Chronic inflammatory mediators enhance prostate cancer development and progression

Biochemical Pharmacology

Volumn 94, Issue 2, 2015, Pages 53-62

  Thapa, Dinesh ^a   Ghosh, Rita ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Castrate resistance; Chemokines; Chronic inflammation; Cytokines; Prostate cancer; Prostate microenvironment

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; AUTACOID;

CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOGENESIS; REVIEW; TUMOR MICROENVIRONMENT; DISEASE COURSE; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

DISEASE PROGRESSION; HUMANS; INFLAMMATION MEDIATORS; MALE; PROSTATIC NEOPLASMS;

EID: 84923922368     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.12.023     Document Type: Note

References (95)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
3. K.S. Sfanos, and A.M. De Marzo Prostate cancer and inflammation: the evidence Histopathology 60 2012 199 215
4. T.C. Jorgenson, W. Zhong, and T.D. Oberley Redox imbalance and biochemical changes in cancer Cancer Res 73 2013 6118 6123
5. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 2010 883 899
6. A.M. De Marzo, E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, and C.G. Drake Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269
7. A. Sciarra, F. Di Silverio, S. Salciccia, A.M. Autran Gomez, A. Gentilucci, and V. Gentile Inflammation and chronic prostatic diseases: evidence for a link Eur Urol 52 2007 964 972
8. N. Salazar, M. Castellan, S.S. Shirodkar, and B.L. Lokeshwar Chemokines and chemokine receptors as promoters of prostate cancer growth and progression Crit Rev Eukaryot Gene Expr 23 2013 77 91
9. L.Y. Fang, K. Izumi, K.P. Lai, L. Liang, L. Li, and H. Miyamoto Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling Cancer Res 73 2013 5633 5646
10. J.L. Luo, W. Tan, J.M. Ricono, O. Korchynskyi, M. Zhang, and S.L. Gonias Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin Nature 446 2007 690 694
11. M. Ammirante, J.L. Luo, S. Grivennikov, S. Nedospasov, and M. Karin B-cell-derived lymphotoxin promotes castration-resistant prostate cancer Nature 464 2010 302 305
12. J.R. Woo, M.A. Liss, M.T. Muldong, K. Palazzi, A. Strasner, and M. Ammirante Tumor infiltrating B-cells are increased in prostate cancer tissue J Transl Med 12 2014 30
13. 4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma Prostate 68 2008 1 10
14. B. Gurel, M.S. Lucia, I.M. Thompson Jr.; P.J. Goodman, C.M. Tangen, and A.R. Kristal Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial Cancer Epidemiol Biomarkers Prev 23 2014 847 856
15. K.S. Sfanos, T.C. Bruno, C.H. Maris, L. Xu, C.J. Thoburn, and A.M. DeMarzo Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing Clin Cancer Res 14 2008 3254 3261
16. L. Fong, P. Carroll, V. Weinberg, S. Chan, J. Lewis, and J. Corman Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer J Natl Cancer Inst 2014 2014
17. C.T. Wu, C.C. Hsieh, C.C. Lin, W.C. Chen, J.H. Hong, and M.F. Chen Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells J Mol Med (Berl) 90 2012 1343 1355
18. N. Chi, Z. Tan, K. Ma, L. Bao, and Z. Yun Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer Int J Clin Exp Med 7 2014 3181 3192
19. R.D. Loberg, C. Ying, M. Craig, L. Yan, L.A. Snyder, and K.J. Pienta CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration Neoplasia 9 2007 556 562
20. C.P. Wong, T.M. Bray, and E. Ho Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages Cancer Lett 276 2009 38 46
21. K. Izumi, L.Y. Fang, A. Mizokami, M. Namiki, L. Li, and W.J. Lin Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation EMBO Mol Med 5 2013 1383 1401
22. P. Zhu, S.H. Baek, E.M. Bourk, K.A. Ohgi, I. Garcia-Bassets, and H. Sanjo Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway Cell 124 2006 615 629
23. E.M. Bekes, B. Schweighofer, T.A. Kupriyanova, E. Zajac, V.C. Ardi, and J.P. Quigley Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation Am J Pathol 179 2011 1455 1470
24. D. Thapa, J.S. Lee, S.Y. Park, Y.H. Bae, S.K. Bae, and J.B. Kwon Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner J Pharmacol Exp Ther 327 2008 353 364
25. D.J. Waugh, and C. Wilson The interleukin-8 pathway in cancer Clin Cancer Res 14 2008 6735 6741
26. A. Seaton, P. Scullin, P.J. Maxwell, C. Wilson, J. Pettigrew, and R. Gallagher Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation Carcinogenesis 29 2008 1148 1156
27. R.K. Singh, and B.L. Lokeshwar The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth Cancer Res 71 2011 3268 3277
28. P.J. Maxwell, J. Coulter, S.M. Walker, M. McKechnie, J. Neisen, and N. McCabe Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma Eur Urol 64 2013 177 188
29. P.J. Maxwell, J. Neisen, J. Messenger, and D.J. Waugh Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells Oncotarget 5 2014 4895 4908
30. D. Thapa, P. Meng, R.G. Bedolla, R.L. Reddick, A.P. Kumar, and R. Ghosh NQO1 suppresses NF-kappaB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis Cancer Res 74 2014 5644 5655
31. S. Araki, Y. Omori, D. Lyn, R.K. Singh, D.M. Meinbach, and Y. Sandman Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer Cancer Res 67 2007 6854 6862
32. J. Zhang, Y. Lu, and K.J. Pienta Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth J Natl Cancer Inst 102 2010 522 528
33. J. Zhang, L. Patel, and K.J. Pienta CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis Cytokine Growth Factor Rev 21 2010 41 48
34. C.D. Chen, and C.L. Sawyers NF-kappaB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer Mol Cell Biol 22 2002 2862 2870
35. R.J. Jin, Y. Lho, L. Connelly, Y. Wang, X. Yu, and L. Saint Jean The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth Cancer Res 68 2008 6762 6769
36. S. Shukla, G.T. MacLennan, P. Fu, J. Patel, S.R. Marengo, and M.I. Resnick Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression Neoplasia 6 2004 390 400
37. H.A. Ismail, L. Lessard, A.M. Mes-Masson, and F. Saad Expression of NF-kappaB in prostate cancer lymph node metastases Prostate 58 2004 308 313
38. V. Fradet, L. Lessard, L.R. Begin, P. Karakiewicz, A.M. Masson, and F. Saad Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer Clin Cancer Res 10 2004 8460 8464
39. R. Jin, H. Yamashita, X. Yu, J. Wang, O.E. Franco, and Y. Wang Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression Oncogene 2014
40. M. Karin NF-kappaB as a critical link between inflammation and cancer Cold Spring Harb Perspect Biol 1 2009 a000141
41. J.A. Burger, and T.J. Kipps CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment Blood 107 2006 1761 1767
42. J. Wang, Y. Shiozawa, J. Wang, Y. Wang, Y. Jung, and K.J. Pienta The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer J Biol Chem 283 2008 4283 4294
43. J. Wang, Y. Sun, W. Song, J.E. Nor, C.Y. Wang, and R.S. Taichman Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis Cell Signal 17 2005 1578 1592
44. Y.X. Sun, J. Wang, C.E. Shelburne, D.E. Lopatin, A.M. Chinnaiyan, and M.A. Rubin Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo J Cell Biochem 89 2003 462 473
45. A. Dubrovska, J. Elliott, R.J. Salamone, G.D. Telegeev, A.E. Stakhovsky, and I.B. Schepotin CXCR4 expression in prostate cancer progenitor cells PLoS ONE 7 2012 e31226
46. W.E. Naugler, and M. Karin The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer Trends Mol Med 14 2008 109 119
47. K. Taniguchi, and M. Karin IL-6 and related cytokines as the critical lynchpins between inflammation and cancer Semin Immunol 26 2014 54 74
48. L. Gu, P. Talati, P. Vogiatzi, A.L. Romero-Weaver, J. Abdulghani, and Z. Liao Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation Mol Cancer Ther 13 2014 1246 1258
49. K. Malinowska, H. Neuwirt, I.T. Cavarretta, J. Bektic, H. Steiner, and H. Dietrich Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor Endocr Relat Cancer 16 2009 155 169
50. D.A. Smith, A. Kiba, Y. Zong, and O.N. Witte Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues Mol Cancer Res 11 2013 1159 1165
51. Z. Culig, and M. Puhr Interleukin-6: a multifunctional targetable cytokine in human prostate cancer Mol Cell Endocrinol 360 2012 52 58
52. Z. Culig Proinflammatory cytokine interleukin-6 in prostate carcinogenesis Am J Clin Exp Urol 2 2014 231 238
53. D.P. Nguyen, J. Li, and A.K. Tewari Inflammation and prostate cancer: the role of interleukin 6 (IL-6) BJU Int 113 2014 986 992
54. A. Rojas, G. Liu, I. Coleman, P.S. Nelson, M. Zhang, and R. Dash IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR Oncogene 30 2011 2345 2355
55. A. Schroeder, A. Herrmann, G. Cherryholmes, C. Kowolik, R. Buettner, and S. Pal Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling Cancer Res 74 2014 1227 1237
56. S. Feng, Q. Tang, M. Sun, J.Y. Chun, C.P. Evans, and A.C. Gao Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2 Mol Cancer Ther 8 2009 665 671
57. C. Liu, Y. Zhu, W. Lou, Y. Cui, C.P. Evans, and A.C. Gao Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells Prostate 74 2014 201 209
58. J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, and X. Filella Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity Clin Cancer Res 12 2006 5578 5586
59. R.K. Singh, and B.L. Lokeshwar Depletion of intrinsic expression of interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs Mol Cancer 8 2009 57
60. X. Liu, J. Peng, W. Sun, S. Yang, G. Deng, and F. Li G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice Tohoku J Exp Med 228 2012 147 156
61. R.D. Loberg, C. Ying, M. Craig, L.L. Day, E. Sargent, and C. Neeley Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo Cancer Res 67 2007 9417 9424
62. K.J. Pienta, J.P. Machiels, D. Schrijvers, B. Alekseev, M. Shkolnik, and S.J. Crabb Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer Invest New Drugs 31 2013 760 768
63. M. Ammirante, S. Shalapour, Y. Kang, C.A. Jamieson, and M. Karin Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts Proc Natl Acad Sci U S A 111 2014 14776 14781
64. Y. Guo, F. Xu, T. Lu, Z. Duan, and Z. Zhang Interleukin-6 signaling pathway in targeted therapy for cancer Cancer Treat Rev 38 2012 904 910
65. C.T. Wu, M.F. Chen, W.C. Chen, and C.C. Hsieh The role of IL-6 in the radiation response of prostate cancer Radiat Oncol 8 2013 159
66. P. Kroon, P.A. Berry, M.J. Stower, G. Rodrigues, V.M. Mann, and M. Simms JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells Cancer Res 73 2013 5288 5298
67. D.G. Duda, S.V. Kozin, N.D. Kirkpatrick, L. Xu, D. Fukumura, and R.K. Jain CXCL12(SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies Clin Cancer Res 17 2011 2074 2080
68. U.M. Domanska, H. Timmer-Bosscha, W.B. Nagengast, T.H. Oude Munnink, R.C. Kruizinga, and H.J. Ananias CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy Neoplasia 14 2012 709 718
69. D. Wong, P. Kandagatla, W. Korz, and S.R. Chinni Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis BMC Urol 14 2014 12
70. U.M. Domanska, J.C. Boer, H. Timmer-Bosscha, M.A. van Vugt, H.D. Hoving, and N.M. Kliphuis CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model Clin Exp Metastasis 31 2014 829 839
71. S. Porvasnik, N. Sakamoto, S. Kusmartsev, E. Eruslanov, W.J. Kim, and W. Cao Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth Prostate 69 2009 1460 1469
72. P.H. Killian, E. Kronski, K.M. Michalik, O. Barbieri, S. Astigiano, and C.P. Sommerhoff Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2 Carcinogenesis 33 2012 2507 2519
73. H.G. Hambright, I.S. Batth, J. Xie, R. Ghosh, and A.P. Kumar Palmatine inhibits growth and invasion in prostate cancer cell: potential role for rpS6/NFkappaB/FLIP Mol Carcinog 2014
74. A.P. Kumar, S. Bhaskaran, M. Ganapathy, K. Crosby, M.D. Davis, and P. Kochunov Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract Clin Cancer Res 13 2007 2784 2794
75. G.P. Swanson, W.E. Jones 3rd, C.S. Ha, C.A. Jenkins, A.P. Kumar, and J. Basler Tolerance of Phellodendron amurense bark extract (Nexrutine(R)) in patients with human prostate cancer Phytother Res 2014
76. J. Gong, J. Xie, R. Bedolla, P. Rivas, D. Chakravarthy, and J.W. Freeman Combined targeting of STAT3/NF-kappaB/COX-2/EP4 for effective management of pancreatic cancer Clin Cancer Res 20 2014 1259 1273
77. S. Davidsson, M. Fiorentino, O. Andren, F. Fang, L.A. Mucci, and E. Varenhorst Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer Cancer Epidemiol Biomarkers Prev 20 2011 2280 2287
78. T.H. Yli-Hemminki, M. Laurila, A. Auvinen, L. Maattanen, H. Huhtala, and T.L. Tammela Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial BJU Int 112 2013 735 741
79. J.C. Nickel, C.G. Roehrborn, M.P. O'Leary, D.G. Bostwick, M.C. Somerville, and R.S. Rittmaster The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial Eur Urol 54 2008 1379 1384
80. D.M. Moreira, J.C. Nickel, L. Gerber, R.L. Muller, G.L. Andriole, and R. Castro-Santamaria Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study Cancer 120 2014 190 196
81. E.M. Kwon, C.A. Salinas, S. Kolb, R. Fu, Z. Feng, and J.L. Stanford Genetic polymorphisms in inflammation pathway genes and prostate cancer risk Cancer Epidemiol Biomarkers Prev 20 2011 923 933
82. S.L. McCarron, S. Edwards, P.R. Evans, R. Gibbs, D.P. Dearnaley, and A. Dowe Influence of cytokine gene polymorphisms on the development of prostate cancer Cancer Res 62 2002 3369 3372
83. L. Dossus, R. Kaaks, F. Canzian, D. Albanes, S.I. Berndt, and H. Boeing PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3) Carcinogenesis 31 2010 455 461
84. J. Sharma, K.P. Gray, L.C. Harshman, C. Evan, M. Nakabayashi, and R. Fichorova Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival Prostate 74 2014 820 828
85. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
86. P.J. Saylor, K.R. Kozak, M.R. Smith, M.A. Ancukiewicz, J.A. Efstathiou, and A.L. Zietman Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer Oncologist 17 2012 212 219
87. K.M. Ignatoski, J. Friedman, J. Escara-Wilke, X. Zhang, S. Daignault, and R.L. Dunn Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy J Interferon Cytokine Res 29 2009 105 112
88. T.B. Dorff, B. Goldman, J.K. Pinski, P.C. Mack, P.N. Lara Jr.; and P.J. Van Veldhuizen Jr. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res 16 2010 3028 3034
89. Z. Culig CXCL8, an underestimated bad guy in prostate cancer Eur Urol 64 2013 189 190
90. J. Karkera, H. Steiner, W. Li, V. Skradski, P.L. Moser, and S. Riethdorf The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study Prostate 71 2011 1455 1465
91. K. Fizazi, J.S. De Bono, A. Flechon, A. Heidenreich, E. Voog, and N.B. Davis Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer Eur J Cancer 48 2012 85 93
92. S.K. Sandhu, K. Papadopoulos, P.C. Fong, A. Patnaik, C. Messiou, and D. Olmos A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors Cancer Chemother Pharmacol 71 2013 1041 1050
93. O.J. Kwon, L. Zhang, M.M. Ittmann, and L. Xin Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin Proc Natl Acad Sci U S A 111 2014 E592 E600
94. D.P. Ankerst, J. Hoefler, S. Bock, P.J. Goodman, A. Vickers, and J. Hernandez Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs. high-grade prostate cancer Urology 83 2014 1362 1367
95. L. Wallner, J. Dai, J. Escara-Wilke, J. Zhang, Z. Yao, and Y. Lu Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice Cancer Res 66 2006 3087 3095